Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey.
Surcel CI, Sooriakumaran P, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjar P, Isbarn H, Ost P, Ploussard G, van den Bergh RC, van Oort IM, Yossepowitch O, Sedelaar JP, Giannarini G; Members of Prostate Cancer Working Group of Young Academic Urologists Working Party; Members of Young Urologists Office of European Association of Urology. Surcel CI, et al. Among authors: van oort im, van den bergh rc. BJU Int. 2015 Apr;115(4):571-9. doi: 10.1111/bju.12796. Epub 2014 Aug 11. BJU Int. 2015. PMID: 24802335
A comparison of machine learning models for predicting urinary incontinence in men with localized prostate cancer.
Hasannejadasl H, Osong B, Bermejo I, van der Poel H, Vanneste B, van Roermund J, Aben K, Zhang Z, Kiemeney L, Van Oort I, Verwey R, Hochstenbach L, Bloemen E, Dekker A, Fijten RRR. Hasannejadasl H, et al. Front Oncol. 2023 Apr 12;13:1168219. doi: 10.3389/fonc.2023.1168219. eCollection 2023. Front Oncol. 2023. PMID: 37124522 Free PMC article.
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.
Tolmeijer SH, Boerrigter E, Sumiyoshi T, Kwan EM, Ng SWS, Annala M, Donnellan G, Herberts C, Benoist GE, Hamberg P, Somford DM, van Oort IM, Schalken JA, Mehra N, van Erp NP, Wyatt AW. Tolmeijer SH, et al. Among authors: van oort im, van erp np. Clin Cancer Res. 2023 Aug 1;29(15):2835-2844. doi: 10.1158/1078-0432.CCR-22-2998. Clin Cancer Res. 2023. PMID: 36996325
A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer.
Boerrigter E, Overbeek JK, Benoist GE, Somford DM, Hamberg P, Tol J, Scholtes B, Willemsen AECAB, Buffart LM, Kessels RPC, Mehra N, van Oort IM, van Erp NP. Boerrigter E, et al. Among authors: van oort im. Eur Urol Oncol. 2024 Dec;7(6):1376-1383. doi: 10.1016/j.euo.2024.02.009. Epub 2024 Mar 13. Eur Urol Oncol. 2024. PMID: 38485614 Free article. Clinical Trial.
Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives.
Vlaming M, Ausems MGEM, Schijven G, van Oort IM, Kets CM, Komdeur FL, van der Kolk LE, Oldenburg RA, Sijmons RH, Kiemeney LALM, Bleiker EMA. Vlaming M, et al. Among authors: van oort im. Fam Cancer. 2024 Jun;23(2):165-175. doi: 10.1007/s10689-024-00377-0. Epub 2024 May 9. Fam Cancer. 2024. PMID: 38722431 Free PMC article.
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
Slootbeek PHJ, Luna-Velez MV, Privé BM, van der Doelen MJ, Kloots ISH, Pamidimarri Naga S, Onstenk HE, Nagarajah J, Westdorp H, van Oort IM, Kroeze LI, Schalken JA, Bloemendal HJ, Mehra N. Slootbeek PHJ, et al. Among authors: van oort im. Theranostics. 2024 Aug 1;14(12):4555-4569. doi: 10.7150/thno.96322. eCollection 2024. Theranostics. 2024. PMID: 39239510 Free PMC article.
172 results